It seems logical that all of the data collected by the team at Biocurex as well as the independent verification by Abott will be submitted for the necessary license to get this to the market. We should all be relieved that it was Biocurex that created the precise "cocktail" which will allow for commercialization on automated analyzers instead of the other way around. This is what will allow Biocurex the ability to showcase how revolutionary this will be on any diagnostic analyzer. The waiting is agonizing, but it appears as though any thoughts of the worst have abated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.